ELYSIUM HEALTH

A pill bottle with footnotes

Somewhere right now, a person is swallowing a capsule and reading a clinical citation off the label.

That is the strange, specific thing Elysium Health built. Most of the supplement aisle runs on vibes - vague promises, a stock photo of a smiling jogger, a word like "vitality" doing all the heavy lifting. Elysium decided to do the opposite. It put a Phase II Mayo Clinic trial on its product, an MIT biologist on its masthead, and a saliva test in its catalog that tells you how old your cells actually behave. The brand is a black rectangle with the word ELYSIUM on it. The substance underneath is a decade of aging research, repackaged for your kitchen counter.

Today the company sells a small shelf of products - Basis, Matter, Signal, Format, Mosaic, Vision - and one test, Index, that reframes the entire pitch. You are not buying youth. You are buying a measurement, and then a way to maybe move the number. It is a quieter promise than "live forever," and a far harder one to fake.

The gap between the lab and the cabinet

Aging research was producing real findings. Almost none of it was reaching real people.

Here is the tension the whole company hangs on. In universities, the biology of aging had become a serious field - sirtuins, NAD+, methylation clocks, the molecular machinery of getting older. In stores, "anti-aging" meant a moisturizer and a marketing budget. The science and the shelf were not on speaking terms.

The reason is boring and structural. Turning a peer-reviewed mechanism into a product people trust requires clinical trials, ingredient sourcing, regulatory care, and a willingness to be boring about claims. Supplement companies rarely bother, because they do not have to. The result: a multi-billion-dollar category mostly disconnected from the research it borrows its vocabulary from.

An investor, an operator, and a biologist walk into a lab

It sounds like the setup to a joke. The punchline was a $71 million company.

In 2014, Eric Marcotulli had a resume that pointed anywhere but here - Bain Capital Ventures, then Sequoia, the well-worn track of a finance career. Dan Alminana brought the operating discipline. And Leonard Guarente brought the part nobody else could: he was the MIT scientist who, in 2000, discovered that sirtuins - proteins that influence aging - depend on a coenzyme called NAD+. The discovery was foundational. It was also sitting in journals, going nowhere near a consumer.

Their bet was that credibility could be a product feature. Instead of hiding the science, they would lead with it: a scientific advisory board eventually grew past 25 researchers, including Nobel laureates. The pitch to a skeptical customer was not "trust us." It was "trust them, and we work with them."

What's actually in the bottle

Six supplements and one test that quietly changes the whole sales pitch.

Basis came first, in 2015: nicotinamide riboside plus pterostilbene, a combination meant to raise NAD+ levels that decline as we age. It is the product the company was effectively founded to make. Then the catalog widened - each item aimed at a different system of the aging body.

Index is the sleight of hand. By measuring biological age from a methylation pattern, Elysium turned a one-time supplement sale into a loop: test, track, retest. You stop buying "a vitamin" and start buying a number you want to watch go down. It is the part of the business that looks less like a vitamin brand and more like a dashboard.

Receipts, not adjectives

A supplement company that runs hospital trials is doing something unusual on purpose.

The strongest evidence that Elysium means the "science-first" line is where it spends its effort. Running Basis through a Phase II trial at Mayo Clinic - testing it against acute kidney injury after cardiac surgery - is not a marketing exercise. It is slow, expensive, and risks producing an inconvenient answer. Most supplement makers would never invite that.

The other proof is institutional company-keeping. Yale's epigenetics work informed Index. Oxford researchers shaped Matter. MIT sits in the founding DNA. When the inevitable patent fight over nicotinamide riboside arrived, the company fought it through to a Federal Circuit ruling in 2023 rather than quietly folding. Conviction, the expensive kind.

• Mayo Clinic: Phase II trial of Basis for post-cardiac-surgery kidney injury.
• Yale University: epigenetics research behind the Index biological-age test.
• University of Oxford: collaboration on the Matter brain-health formula.
• MIT: Guarente's Glenn Center, where the NAD+ science originated.

Make the lab accessible

Not immortality. Access.

Strip away the capsules and the catalog, and the mission is narrower than the category's usual grandiosity: take what aging researchers already know, and hand it to people in a form they can actually use. Guarente, as chief scientist, anchors that to fundamentals - decades on the SIR2 gene before it ever became a product. The company frames itself less as a wellness brand and more as a translation layer between the journal and the medicine cabinet.

It is a useful kind of modesty. "We will help you live forever" is unfalsifiable and unserious. "We will measure your biological age and sell you research-backed ways to influence it" is a claim you can test, argue with, and hold the company to. Elysium chose the version that can be wrong.

Why the number matters next

If biological age becomes a metric people watch, the company that taught them to watch it has a head start.

Longevity is having a moment - investors, clinics, and a wave of brands all racing to sell the same dream. Elysium's edge is unglamorous: it has been doing the slow, evidentiary version since before it was fashionable. The bet for the next decade is that consumers stop accepting "anti-aging" as a feeling and start demanding it as a measurement. If they do, a saliva test that reports biological age across body systems stops looking like a novelty and starts looking like infrastructure.

The risks are real. The science of aging supplements is still contested, the longevity market is crowding fast, and a number going down can be hard to attribute to any one capsule. But the through-line holds: the gap between the lab and the cabinet is still there, and Elysium is still trying to close it one footnoted bottle at a time.

A decade ago that scene did not exist. Aging research stayed in the journals; the supplement aisle stayed in the dark. Elysium built the bridge between them - and turned "how old are you?" into a question your spit can answer. The branding is still a calm black rectangle. The ambition underneath it is anything but.